Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217104 | 0.90 | VCAM1 (0.55) | VCAM1MAPTKDM4ELMNAALDH1A1 | |
| SCHEMBL5217118 | 0.86 | VCAM1 (0.51) | VCAM1MAPTKDM4ELMNAALDH1A1 | |
| SCHEMBL29930566 | 0.86 | VCAM1 (0.51) | VCAM1MAPTKDM4ELMNAALDH1A1 | |
| SCHEMBL20839509 | 0.84 | TPMT (0.54) | VCAM1MAPTKDM4ELMNAALDH1A1 | |
| SCHEMBL443612 | 0.84 | ALDH1A1 (0.51) | VCAM1MAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL4199372 | 0.84 | VCAM1 (0.50) | VCAM1MAPTKDM4ELMNAALDH1A1 | |
| SCHEMBL31161317 | 0.84 | VCAM1 (0.52) | VCAM1MAPTKDM4ELMNAALDH1A1 | |
| SCHEMBL15432231 | 0.84 | VCAM1 (0.52) | VCAM1MAPTKDM4ELMNAALDH1A1 | |
| SCHEMBL18031418 | 0.83 | ALDH1A1 (0.49) | VCAM1MAPTKDM4ELMNAALDH1A1 | |
| SCHEMBL1759189 | 0.83 | MAPT (0.50) | VCAM1MAPTKDM4ELMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227762-A1 | AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | BEONE MEDICINES I GMBH (CH) | 2022-07-21 | — | — | US | disclosed |
| WO-2022135365-A1 | DISUBSTITUTED CYCLOPENTANE KINASE INHIBITORS | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2022-06-30 | — | — | WO | disclosed |
| CN-113891880-A | Amide substituted imidazo compounds as selective inhibitors of indoleamine 2, 3-dioxygenase | 百济神州有限公司 | 2022-01-04 | — | — | CN | disclosed |
| WO-2020233677-A1 | PROCESS FOR PREPARING AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS | BEIGENE (BEIJING) CO., LTD. (CN) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020233676-A1 | AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS AS SELECTIVE INHIBITORS OF INDOLEAMINE 2, 3-DIOXYGENASES | BEIGENE, LTD. (KY) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020233676-A1 | AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS AS SELECTIVE INHIBITORS OF INDOLEAMINE 2, 3-DIOXYGENASES | BEIGENE, LTD. (KY) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020156323-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020119606-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-06-18 | — | — | WO | disclosed |
| US-10202383-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-02-12 | — | — | US | disclosed |
| US-20180291025-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2018-10-11 | — | — | US | disclosed |
| US-20080249089-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-10-09 | — | — | US | disclosed |
| US-7407955-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-08-05 | — | — | US | disclosed |
| US-7217711-B2 | Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-15 | — | — | US | disclosed |
| EP-1636216-A1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-22 | — | — | EP | disclosed |
| US-20050171093-A1 | New piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutial compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-04 | — | — | US | disclosed |
| US-20050020654-A1 | Novel PPAR agonists, pharmaceutical compositions and uses thereof | BETHESDA PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | disclosed |
| US-20050009829-A1 | Benzimidazole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-13 | — | — | US | disclosed |
| WO-2004101553-A1 | BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004082621-A2 | NOVEL PPAR AGONISTS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BETHESDA PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040097510-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202383-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP8, DPP4, DPP3 | VCAM1 4116/4885MAPT 511/4885KDM4E 829/4885 |
| US-20050171093-A1 | New piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutial compositions | DPP4, DPP3, DPP7 | VCAM1 4274/4885MAPT 486/4885KDM4E 844/4885 |
| US-20050020654-A1 | Novel PPAR agonists, pharmaceutical compositions and uses thereof | PPARG, PPARD, PPARA | VCAM1 1470/4885MAPT 3335/4885KDM4E 3275/4885 |
| US-20050009829-A1 | Benzimidazole-derivatives as factor Xa inhibitors | F12, F11, F5 | VCAM1 509/4885MAPT 4847/4885KDM4E 1256/4885 |
| US-20180291025-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | VCAM1 4116/4885MAPT 511/4885KDM4E 829/4885 |
| US-20080249089-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP3 | VCAM1 4196/4885MAPT 423/4885KDM4E 779/4885 |
| US-20220227762-A1 | AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | IDO1, IDO2, AADAC | VCAM1 4434/4885MAPT 2047/4885KDM4E 491/4885 |
| US-20040097510-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP8, DPP4, DPP3 | VCAM1 3353/4885MAPT 1029/4885KDM4E 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.